课题基金 / 基金详情

Evaluating novel diagnostics and enabling preventive measures for childhood tuberculosis between the UK and partners in Sub-Saharan Africa

Evaluating novel diagnostics and enabling preventive measures for childhood tuberculosis between the UK and partners in Sub-Saharan Africa
英国与撒哈拉以南非洲合作伙伴之间评估儿童结核病的新型诊断方法和实施预防措施
批准号:
MC_EX_MR/P024270/1
负责人:
Beate Kampmann
金额:
$79.09万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

Beate Kampmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This project aims to develop and validate better diagnostic tools for children with TB (Find and Treat), as well as looking at implementation of preventive therapy for those already infected but not yet ill, but who might progress to disease if not receiving the recommended intervention- (Screen and Prevent).Importance of TB in LMIC:Around 1 million children fall ill from TB each year and 140 000 die. Many countries struggle to deliver the age-stratified notifications for TB in children to the WHO, and there is reluctance to engage in diagnosing and treating TB in children in many settings, as staff feel ill equipped to confirm a "gold standard" diagnosis, based on microbiological evidence. This situation is pertinent in Africa and continues to lead to unnecessary morbidity and mortality and a reservoir of cases for the future. The roadmap for the elimination of TB sets priorities for achieving global TB control and within this effort, childhood TB has been identified as a neglected problem, but of great importance for overall TB control (WHO Global Plan for TB).This requires two interventions: 1. to appropriately diagnose the cases and place on treatment -find and treat- and 2. to prevent secondary cases in TB-exposed children, which can be done successfully by delivering preventive medication- screen and prevent.Why is it more difficult to diagnose TB in children?Due to the limited number of mycobacteria contained in their sputa, conventional microbiological diagnostics perform poorly in children. Unless more sensitive diagnostics for paucibacillary disease can be developed, it is unlikely that the current situation of two thirds of children receiving treatment for TB without a confirmed diagnosis will change. Host-derived biosignatures in blood or urine therefore hold promise for development into point-of care tests for childhood TB.What do we want to do?We have considerable experience in the management of childhood TB in both the UK and The Gambia, and this project aims to involve new partners in Africa to find and treat children with TB using existing and new diagnostics. We have already developed such new tests but they need to be further validate also in children who have HIV or malnutrition. We will therefor recruit a large prospective court of children likely o have TB to validate the new diagnostics.In addition, we want to work the National TB programs (NTP) in the partner countries to implement a preventive strategy, as supported by the WHO but not implemented on the ground. We want to understand the bottlenecks within the care path and train members of the NTP to recognise TB in children and take the necessary preventive steps to avoid secondary cases in families. Based on the UK model, we have already established a screen-and-prevent- program of contact screening for children exposed to TB in their households in The Gambia, which has the support of the NTP. Our find and treat and screen and prevent activities have increased the case notifications by 50% over the last 3 years. This approach now requires full integration into the NTP programs in other countries and systematic evaluation to determine its long term impact on national TB figures also in our partner countries. It could serve as an important model for the WHO strategy o improve prevention of TB worldwide but each country might have specific requirements and our project will deliver data from 4 different African settings to inform the recommendations.We expect that our work can improve TB control and that we can create a network of excellence with specialist knowledge for childhood TB in Africa, as we have already done in Europe.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.vaccine.2019.11.060
发表时间: 2020-02-24
期刊: Vaccine
影响因子: 5.5
作者: [Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, Netea MG, Liu M, Potluri LP, Sanchez-Schmitz G, Husson R, Ozonoff A, Kampmann B, van Haren SD, Levy O]
通讯作者: Levy O
DOI: 10.1016/s1473-3099(18)30157-9
发表时间: 2019-03
期刊: The Lancet. Infectious diseases
影响因子: --
作者: [Basu Roy R, Whittaker E, Seddon JA, Kampmann B]
通讯作者: Kampmann B
DOI: 10.3389/fgene.2018.00457
发表时间: 2018
期刊: Frontiers in genetics
影响因子: 3.7
作者: [Bah SY, Forster T, Dickinson P, Kampmann B, Ghazal P]
通讯作者: Ghazal P
Conducting clinical research in a resource-constrained setting: lessons from a longitudinal cohort study in The Gambia.
在资源受限的环境中进行临床研究:冈比亚纵向队列研究的教训。
DOI: 10.1136/bmjgh-2021-006419
发表时间: 2021-08
期刊: BMJ global health
影响因子: 8.1
作者: [Imam A, Wariri O, Dibbasey T, Camara A, Mendy A, Sanyang AN, Ceesay M, Jallow S, Jallow AE, Bah K, Johnson N, Trawally E, Sowe D, Darboe A, Kampmann B, Idoko OT]
通讯作者: Idoko OT
Immunising Pregnant women and infants network- IMPRINT
Thematic Support - Vaccines and Immunity
IMPRINT: IMmunising PRegnant women and INfants neTwork
IMPRINT: IMmunising PRegnant women and INfants neTwork
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: